Conversion from calcineurin to mammalian target of rapamycin inhibitors in liver transplantation: A meta-analysis of randomized controlled trials

Transplantation

Volumn 100, Issue 3, 2016, Pages 621-629

  Glover, Thomas E ^a   Watson, Christopher J E ^a   Gibbs, Paul ^a   Andrew Bradley, J ^a   Ntzani, Evangelia E ^b,c   Kosmoliaptsis, Vasilis ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CREATININE CLEARANCE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; MOUTH ULCER; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; WOUND HEALING IMPAIRMENT; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

CALCINEURIN INHIBITORS; CHI-SQUARE DISTRIBUTION; DRUG SUBSTITUTION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; PROTEIN KINASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84959906831     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001006     Document Type: Article

References (42)

1. Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant. 2014;14(Suppl 1):69-96.
2. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe.Areport from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675-688.
3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
4. LaMattina JC, Mezrich JD, Fernandez LA, et al. Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. Clin Transplant. 2013;27:193-202.
5. Garces G, Contreras G, Carvalho D, et al. Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus. Clin Nephrol. 2011;75:150-157.
6. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
7. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 1998;30:2192-2194.
8. Watson CJ, Bradley AJ. Sirolimus and everolimus: inhibitors of mammalian target of rapamycin in liver transplantation. Transplant Rev. 2006;20: 104-114.
9. Diekmann F, Andrés A, Oppenheimer F. mTOR inhibitor-associated pro-teinuria in kidney transplant recipients. Transplant Rev (Orlando). 2012; 26:27-29.
10. Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014;14:356-366.
11. Pengel L, Morris P. The transplant library of randomized controlled trials and systematic reviews. Transplantation. 2011;92:613-616.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700.
13. Herlenius G, Felldin M, Nordén G, et al. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial. Transplant Proc. 2010;42:4441-4448.
14. Watson CJ, Gimson AE, Alexander GJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl. 2007;13:1694-1702.
15. Shenoy S, Hardinger KL, Crippin J, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation. 2007;83:1389-1392.
16. Teperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor-free my-cophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013;19:675-689.
17. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everoli-mus after liver transplantation-PROTECT. Am J Transplant. 2012;12: 1855-1865.
18. Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant. 2012;12:694-705.
19. Eisenberger U, Sollinger D, Stickel F, et al. Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor. Clin Transplant. 2009;23:499-504.
20. De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009;15: 1262-1269.
21. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacro-limus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12:3008-3020.
22. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glo-merular filtration rate. Ann Intern Med. 2009;150:604-612.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130:461-470.
25. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcine-urin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant. 2010;10: 2252-2262.
26. Villamil FG, Gadano AC, Zingale F, et al. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors. Liver Int. 2014;34: 1513-1521.
27. Fischer L, Saliba F, Kaiser GM, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study. Transplantation. 2015;99:1455-1462.
28. Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant. 2014;14:701-710.
29. Asrani SK, Leise MD, West CP, et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology. 2010;52:1360-1370.
30. Londoño MC, Rimola A, O'Grady J, et al. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol. 2013; 59:872-879.
31. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000;356:194-202.
32. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol. 2001;12:1059-1071.
33. MacDonald AS; RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71:271-280.
34. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation. 2004;78:264-268.
35. Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors: what role in liver transplantation? J Hepatol. 2011;55:1441-1451.
36. Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant. 2014;2014:845438.
37. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis denovo. Clin J Am Soc Nephrol. 2007;2:326-333.
38. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepato-cellular carcinoma. Hepatology. 2010;51:1237-1243.
39. Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosup-pression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008;14:633-638.
40. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl. 2009;15:1834-1842.
41. Chan AJ, Lake JR. Immunosuppression in HCV-positive liver-transplant recipients. Curr Opin Organ Transplant. 2012;17:648-654.
42. Shah M, Shankar A, Gee I, et al. A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients. Aliment Pharmacol Ther. 2015;41:379-392.